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18F-FDG-PET/CT for the Assessment of the Contralateral Neck in
Patients with Head and Neck Squamous Cell Carcinoma (HNSCC)
Nikos Kastrinidis, MD; Felix P. Kuhn, MD; Thomas F. Hany, MD; Nader Ahmad, MD;
Gerhard F. Huber, MD; Stephan K. Haerle, MD
Objectives/Hypothesis: The aim was to compare the value of 18-Fluoro-Deoxyglucose (18F-FDG) positron emission
tomography (PET)/computed tomography (CT) regarding contralateral lymph node (LN) metastasis in the neck.
Study Design: Retrospective analysis of 61 patients staged by 18F-FDG-PET/CT.
Methods: Cytology/histology served as a reference standard. Further, metabolic midline invasion (MI) of the primary
tumor and the presence of bilateral LN metastases were assessed.
Results: A true positive rate in the ipsilateral neck of 80% versus 65% in the contralateral neck was found (P 5 0.067).
Median-standardized uptake value (SUV)-max for suspicious LN ipsilaterally was 7.6 versus 5.8 contralaterally (P 5 0.038).
There was no positive correlation between metabolic MI and bilateral metastasis (P 5 0.82).
Conclusions: The rate of true positive detected LN by 18F-FDG-PET/CT is less on the contralateral neck side; therefore,
all suspicious LNs should be verified by cytology. A high SUV in the contralateral neck suggests metastatic disease regardless
of nodal size. Metabolic MI needs to be addressed carefully as it was not predictive for bilateral LN involvement.
Key Words: 18F-FDG-PET/CT, staging, contralateral neck, head and neck squamous cell carcinoma.
Level of Evidence: 4.
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INTRODUCTION
Patients who present with advanced head and neck
squamous cell carcinoma (HNSCC) often have associated
cervical lymph node metastases, which are a significantly
negative prognostic factor. Accurate pretreatment staging
of the cervical lymph node basins is essential for proper
treatment planning, especially in patients with advanced
T stage tumors where the probability of bilateral cervical
lymph nodes metastases is high.1,2 Regional lymph node
involvement is one of the utmost prognostic factors with
regard to the patient’s outcome.3 In patients with multiple
lymph node metastases, the prognosis drops by approxi-
mately 50%.4 These patients present mostly in a later
stage of tumor development by suffering from a tumor
showing a midline invasion and expansion of the primary
through multiple levels.5 To date, most studies on initial
nodal staging have focused on computed tomography
(CT), magnetic resonance imaging (MRI), and ultrasound-
guided fine needle aspiration cytology (USgFNAC).6–10
Since the introduction of 18-Fluoro-Deoxyglucose (18F-
FDG) positron emission tomography (PET) and the fusion
of 18F-FDG-PET with CT, some authors have advocated
metabolic imaging for neck staging.11–13 Recent studies
have clearly shown improved accuracy for fused 18F-
FDG-PET/CT over 18F-FDG-PET alone.14–16 However,
there is still no consensus on the best imaging modality.
The reported sensitivity and specificity using USgFNAC
for neck staging varies from 63% to 100%, respectively.7
Stoeckli et al.17 recently found USgFNAC to be the most
accurate initial neck staging method, whereas Veit-
Haibach et al.18 proposed 18F-FDG-PET/CT as the first
line imaging method for neck staging.
A well-known drawback of 18F-FDG-PET/ CT is the
high rate of false positive findings due to inflammation
or movement of the patient during the examination,19,20
resulting in a lower positive predictive value. Further
investigations create additional costs and burden the
patient. Moreover, reports have recently suggested that
there could be a difference in the accuracy of 18F-FDG-
PET/ CT in staging the ipsilateral versus the contralat-
eral neck. The primary aim of this article is to critically
examine this institution’s experience to determine if
18F-FDG-PET/ CT scan can be reliably used to initially
stage the contralateral neck with advanced T stage
HNSCC.21 Our clinical impression over the years is in
line with these suggestions, and it leads to the presump-
tion that 18F-FDG-PET/ CT findings may be false
positive more often for the contralateral side, compared
to the findings on the ipsilateral neck side (Fig. 1). A
well-known risk factor for bilateral cervical lymph node
metastasis is the midline-invasion of the primary.22 Due
to the anatomic distribution of the lymphatic drainage
in the head and neck, the localization of the primary is one
From the Department of Otolaryngology, Head and Neck Surgery
(N.K., N.A., G.F.H., SK.K.H.), and the Division of Nuclear Medicine, Division of
Nuclear Medicine, Department of Medical Radiology (F.P.K., T.F.H.),
University Hospital Zurich, Zurich, Switzerland
Editor’s Note: This Manuscript was accepted for publication
November 26, 2012.
The authors have no funding, financial relationships, or conflicts
of interest to disclose.
Send correspondence to Stephan K. Haerle, MD, Department of
Otolaryngology, Head and Neck Surgery, University Hospital Zurich,
Frauenklinikstrasse 24, CH-8091 Zurich, Switzerland.
E-mail: Stephan.Haerle@usz.ch
DOI: 10.1002/lary.23944
Laryngoscope 00: Month 2012 Kastrinidis et al.: Contralateral Neck Staging Using 18F-FDG-PET/CT
1
of the main factors influencing lymphatic metastases.23,24
Well-lateralized primaries tend to metastasize to the ipsi-
lateral side only, whereas tumors involving structures of
the midline tend to metastasize to both sides5 (Fig. 2).
The aims of this study were threefold: 1) to compare
the rate of occurrence of true positive lymph nodes in
18F-FDG-PET/ CT by assessing the ipsi- and contralat-
eral side of the neck (the standard of reference was the
FNAC or histopathology result); 2) to determine a cutoff
standardized uptake value (SUV) max, which could be
used as a reliable tool to differentiate from true regional
metastases and false positive lymph node involvement;
3) to investigate an association of midline invasion of
the primary in 18F-FDG-PET/ CT, with true positive
findings on the contralateral side.
MATERIALS AND METHODS
Patients
A total of 515 patients suffering from HNSCC were pri-
marily assessed by 18F-FDG-PET/ CT between 2001 and 2008
at the Department of Otolaryngology, Head and Neck Surgery,
University Hospital Zurich, Switzerland. This patient cohort
does not represent a consecutive group of all patients diagnosed
with HNSCC within the given time frame. The cohort consisted
mainly of patients with advanced disease (T3/ T4 and/ or N2/ N3,
respectively), who were referred for 18F-FDG-PET/ CT to exclude
distant metastases at the time of initial staging. The 18F-FDG-
PET/ CT was not used for assessing occult disease. For this
study, patients with a history of previous neck dissection or
radiotherapy, or with local or regional recurrence were excluded.
All 515 radiological reports were initially reviewed by a head
and neck surgeon (N.K.). According to these reports, 18F-FDG-
PET/ CT demonstrated increased 18F-FDG uptake bilaterally in
91 cases. Nodes were judged as metastatic if the uptake was
clearly higher than that in the background tissue, and if the
uptake matched with a lymph node on the corresponding CT
image. Thirty patients were excluded due to missing data; there-
fore, a total of 61 patients were included for complete analysis.
This work was conducted in accordance with the local guidelines
established by the ethics committee for a retrospective evalua-
tion. All 61 18F-FDG-FDG-PET/ CT scans were reviewed by two
nuclear medicine specialists, with specific emphasis on regional
neck metastasis (H.T.F.; K.F.P.). The metabolic activity and the size
of all suspicious lymph nodes were retrospectively analysed.
Standard of Reference
As a routine initial staging procedure, all patients at our
institution underwent ultrasound guided fine needle aspiration
(USgFNAC) for neck staging, meaning that all sonografically
suspicious lymph nodes were fine needle aspirated under ultraso-
nogaphic (US) guidance. The ultrasound examinations were
performed by head and neck surgeons certified for US imaging
according to the Swiss Ultrasound Society (SGUM). During the
above-mentioned time period, a Siemens Sonoline Antares
Fig. 1. Squamous cell cancer of the left mesopharynx, midline crossing, only ipsilateral lymph node metastasis. From left to right:
“Maximum intensity projection” PET image (MIP), axial PET, CT, and fused PET/ CT. SUV primary tumor 16 (red arrow), ipsilateral lymph
node 7.2 (blue arrow), contralateral lymph node 4.0 (green arrow).
Fig. 2. Squamous cell cancer of the left vallecula, midline crossing, bilateral lymph node metastasis. From left to right: “Maximum intensity
projection” PET image (MIP), axial PET, CT, and fused PET/ CT. SUV primary tumor 9.7 (red arrow), ipsilateral lymph node 4.1 (blue arrow),
contralateral lymph node 4.3 (green arrow).
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ultrasonograph with a 10.5-MHz linear transducer (Siemens
Medical Solutions, Erlangen, Germany) was used. For biopsies, a
24-gauge needle attached to a 10-ml syringe and syringe holder
(Cameco Ltd., London, UK) was chosen. Under ultrasound guidance,
the needle was gently pushed forward in a longitudinal direction to
the transducer, through the skin into the middle of the mass. The
following ultrasound characteristics of the examined lymph nodes
were evaluated: a minimal axial diameter of 7 mm for level II and
5 mm for the remainder of the neck lymph nodes; a diameter of <2,
comparing long- to short axis or spherical shape (supportive criterion
in borderline sizes); and hypoechoic sonomorphology.
A total of 54 patients underwent cytological verification
for every suspicious lymph node detected by 18F-FDG-PET/ CT;
whereas in seven patients, the histopathology of the neck dis-
section served as the standard of reference. The cytological and
histological specimens, respectively, were examined according to
an institutionally standardized pathology protocol.
Imaging Protocol
The inline PET/ CT system (Discovery LS or Discovery ST
with a multi-slice helical CT, GE Healthcare) enabled the acquisi-
tion of coregistered CT and PET images in the same session. Prior
to injection of a standard dose of approximately 350 MBq of FDG,
patients fasted for at least 4 hours. The scan started approxi-
mately 60 minutes after the injection. All patients were examined
in the supine position with arms down. The CT data were acquired
during free shallow breathing with 140 kV, 80 mA, 0.5 second tube
rotation, 4.25-mm section thickness, and a scan length of 867 mm
with 22.5 second scan time. The PET data were acquired immedi-
ately after the CTwith a scan time of 3 minutes per table position,
resulting in a total scan time of 18 minutes for six table positions
from head to pelvic floor. The CTwas used for the reconstruction of
the PET images with regard to attenuation correction. The PET
reconstruction process used a standard 2-dimensional iterative
algorithm [ordered subset expectation maximization (OSEM)].
The measurement of the lymph nodes and the outline of
volumes of interest (VOI) for the calculation of SUV max were
done by a nuclear medicine physician with vast experience in
neuroradiology. The SUV corresponds to the measured tissue
concentration (Bq/ ml) divided by the injected dose normalized
to the patient’s weight (g). The SUV max corresponds to the
voxel within a VOI with the highest activity and is calculated
by commercially available software (Advantage workstation,
software version 4.4, GE Healthcare).
Statistical Analysis
Both means of SUV max and of lymph node size of the con-
tralateral and ipsilateral neck side were compared by using the
unpaired or paired student t test when appropriate. Variations of
proportion were examined through Chi square or the Fisher
exact tests. A P value of <0.05 was considered statistically signif-
icant. Choosing a confidence interval of 0.95, P values <0.01
were considered to be significant. True positive rate, false posi-
tive rate, and SUV cutoff values of the optimal test performance
to detect ipsi- and contralateral lymph node metastases were cal-
culated by the area under the curve, generated according to the
receiver operating characteristic method (ROC). All statistical
analyses were performed with SPSS 17.0 software.
RESULTS
Patient’s and Tumor Characteristics
Between 2001 and 2008, 91/ 515 (17.6%) radiologi-
cal reports mentioned 18F-FDG-PET/ CT, showing
bilateral suspicious cervical metabolic 18F-FDG-uptake.
Due to missing data, 30 patients needed to be excluded,
resulting in 61 patients eligible for further evaluation.
Patient and tumor characteristics are shown in Table I.
Forty-seven out of 61 patients (77%) presented with
advanced stage disease (Stage III/ IV [International
Union against Cancer (UICC), 1997]).
The Analysis of the Ipsi- And Contralateral
Suspicious Lymph Nodes Detected By
18F-FDG-PET/ CT
Suspicious ipsilateral 18F-FDG-uptake could be
confirmed by cytology/ histology in 49/ 61 cases. This
translates to a true positive rate for the ipsilateral neck
of 80%. On the contralateral side, 18F-FDG-PET/ CT
was able to detect 40/ 61 true positive lymph node me-
tastases confirmed by cytology/ histology. This translates
to a true positive rate for the contralateral side of 65%.
There was no significant difference found between both
sides (P 5 0.067). In comparison, suspicious ipsilateral
findings on the ultrasound were confirmed by cytology/
histology in 51/ 61 cases. This translates to a true posi-
tive rate for the ipsilateral neck of 83%. On the
contralateral side, ultrasound was able to detect 48/ 61
true positive lymph node metastases, confirmed by cytol-
ogy/ histology. This translates to a true positive rate for
the contralateral side of 79%.
SUV Max of Suspicious Bilateral Lymph Node
Involvement
Statistical analysis revealed a mean SUV max for
the ipsilateral lymph nodes of 7.6 (range, 1.9–22.7), com-
pared to 5.8 (range, 2.1–39.6) for the contralateral side
(P 5 0.038). Further analysis revealed significant differ-
ences between true positive and false positive findings
for both neck sides: The ipsilateral mean SUV max for
the true positives was 8.4 (range, 1.9–22.7), compared to
4.4 (range, 2–9.7) found for the false positives (P 5
0.01). Looking at the contralateral side, the mean SUV
TABLE I.
Patient’s and Tumor Characteristics (n 5 61).
Women 20 (32.8%)
Men 41 (67.2%)
Mean (years) 60
Range 33–84
Location of primary HNSCC
Nasopharynx 5 (8.2%)
Oral cavity 30 (49.2%)
Oropharynx 10 (16.4%)
Hypopharynx 8 (13.1%)
Larynx 8 (13.1%)
T classification T1 3 (4.9%)
T2 11 (18%)
T3 15 (24.6%)
T4 32 (52.5%)
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max of the true positives was 7.3 (range, 2.1–39.6), com-
pared to 3.3 (range, 1.5–8) found for the false positives
(P 5 0.016). There was no significant difference (P 5
0.43) for comparison between the mean SUV max of true
positives on the ipsilateral and the contralateral side
(Table II). A cutoff SUV max of 3.7 or higher on the ipsi-
lateral side (translating to a sensitivity of 87% and a
specificity of 64%) and 3.5 or higher on the contralateral
side (translating to a sensitivity of 74% and a specificity
of 71%) was found to be most accurate in differentiating
between physiological or pathological 18F-FDG-uptake
using ROC-analysis (Figs. 3 and 4).
Analysis of the Lymph Node Size Using
18F-FDG-PET/CT
The most current reliable criterion for evaluation of
the integrity of lymph nodes and the selection of which
lymph node should be aspirated is the size measured as the
minimal axial diameter (MAD) during ultrasound.25–27 In
our series, the mean MAD of the suspicious lymph nodes
on the ipsilateral side was 1.7 cm (range 0.5–4.7), compared
to the lymph nodes on the contralateral side with a mean
MAD of 1.3 cm (range 0.7–4.1; P value 0.001; Table II).
Midline Invasion of the Primary and
Contralateral Lymph Node Involvement
Detected by 18F-FDG-PET/ CT
Out of 41/ 61 patients showing a midline invasion
of the primary in the 18F-FDG-PET/ CT scan, 26 (63%)
patients were found to have a true positive contralateral
cervical lymph node metastasis. In the remaining 20
primaries without midline invasion, a true positive con-
tralateral lymph node metastasis was found in 14 cases
(70%; P 5 0.82).
DISCUSSION
In this study, we demonstrated a difference in the
detection of regional metastases between the ipsi- and
contralateral side of the neck by using 18F-FDG-PET/
CT in patients suffering from HNSCC.
TABLE II.
Correlation Between SUV-Max of Both Neck Sides and Lymph Node Size (n 5 56).
SUV-Max Lymph Node P Value
Ipsilateral 7.6 (SD 6 4.8; range 1.9–22.7) P value 0.038
Contralateral 5.8 (SD 6 6.0; range 2.1–39.6)
SUV-Max True Versus False Positive Lymph Nodes
Ipsilateral true positive 8.4 (SD 6 4.9; range 1.9–22.7) P value 0.01
Ipsilateral false positive 4.4 (SD 6 2.4; range 2–9.7)
Contralateral true positive 7.3 (SD 6 7.2; range 2.1–39.6) P value 0.016
Contralateral false positive 3.3 (SD 6 1.5; range 1.5–8)
Lymph Node Size
Ipsilateral 1.7 cm (SD 6 0.94; range 0.5–4.7) P value 0.001
Contralateral 1.3 cm (SD 6 0.62; range 0.7–4.1)
Fig. 3. Cutoff SUV max ipsilateral of 3.7 (sensitivity 5 87%; speci-
ficity 5 64%).
Fig. 4. Cutoff SUV max contralateral 3.5 (sensitivity 5 74%; speci-
ficity 5 71%).
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In recent years, the application of 18F-FDG-PET/
CT in diagnosis, staging, and posttherapeutic surveil-
lance has become a well-accepted method for head and
neck oncologists/ surgeons.6–9,28,29 Most authors agree
that 18F-FDG-PET/ CT is a reliable staging method to
exclude distant metastases30,31 and to detect second pri-
maries in high risk patients.1 However, there is still no
consensus on its value for neck staging. A number of
studies have compared metabolic imaging to conven-
tional imaging methods, such as CT or MRI for initial
neck staging.6–10 Stoeckli et al. prospectively compared
18F-FDG-PET/ CT to CT, US, and USgFNAC, respec-
tively.17 They found a rate of 16% in overstaging the
N2c- neck by using 18F-FDG-PET/ CT, compared to 13%
for CT and 7% for USgFNAC. Based on these results, we
used cytology workup of every suspicious lymph node as
a standard of reference next to the histological workup
after neck dissection.
A recent study by Kim et al. comparing the meta-
bolic findings with the histological workup of the neck
dissection found 18F-FDG-PET/ CT to be less sensitive
in detecting contralateral than ipsilateral neck meta-
stases.21 These results are in line with our clinical
impression over the years, leading to this retrospective
analysis of the value of 18F-FDG-PET/ CT, with special
emphasis on staging the contralateral neck. Using a
retrospective study design, we were able to show a dif-
ference in detecting true positive findings for the ipsi-
(80%) versus the contralateral side (65%) using 18F-
FDG-PET/ CT. Although our findings are not statisti-
cally significant, they show an important trend. Further,
when comparing these findings with the results of US
(83% true positive rate for ipsilateral side, and 79% for
the contralateral side, respectively), the limitation of
18F-FDG-PET/ CT as being less specific on the contralat-
eral side becomes obvious.
While using the FNA cytology or the histopathology
of the neck dissection as a standard of reference, other
possible parameters that could be taken for an analogi-
cal evaluation have to be mentioned. For example, it is
reasonable to inquire about follow-up data on regional
control for initial FNA negative untreated patients.
However, our cohort consisted entirely of patients with
advanced disease (T3/ T4 and/ or N2/ N3, respectively).
Out of them, we only evaluated those with bilateral
FDG-accumulation in the 18F-FDG-PET/ CT. Although
having, as reported, false positive accumulation in the
18F-FDG-PET/ CT, compared to the findings of the FNA
cytology or the histopathology of the neck dissection, the
concept of therapy included almost entirely a bilateral
radiation of the neck. Therefore, a detailed follow-up
regarding this specific question in our population is not
available and reflects a limitation of our study.
The mean SUV max is significantly increased on
the ipsilateral side, compared to the contralateral side
(P 5 0.038). One might argue that this is due to the dif-
ferent lymph node sizes we found for the two sides of
the neck (P 5 0.001). However, no significant difference
was found comparing the mean SUV max for the true
positives on both sides, but SUV max values between
the true and false positive lymph nodes on each side
were significantly different. Therefore, we were able to
strengthen our subjective impression that low SUV max
of the contralateral, compared to the ipsilateral 18F-
FDG-uptake in lymph nodes, are likely false positive.
Additionally, analyzing the smallest true positive lymph
nodes in our series, the smallest ipsilateral node was 0.5
cm in axial diameter, compared to 0.7 cm contralaterally.
These results tend to emphasize how relatively unimpor-
tant lymph node size is regarding bilateral metabolic
activity, whereas SUV max seems to be reliable when
interpreting 18F-FDG-accumulations regarding this
specific issue. In summary, a high SUV max in the con-
tralateral neck suggests metastatic disease, regardless of
nodal size.
Other authors have reported a cut-off SUV max to
differentiate between true positive and false positive
18F-FDG-PET/ CT findings when staging the neck. Pan-
sare et al.32 found an SUV max > 2.5 most likely to be
malignant, whereas an SUV max < 2.5 was malignant
in only 13% of cases. In a 2011 retrospective study,
Nguyen et al.33 found an SUV max threshold for cervical
lymph nodes of 2.2 to be the most accurate (sensitivity
of 98% and specificity of 83%) in differentiating between
malignant and benign tissue. Other studies have
reported SUV max thresholds of 1.9 to 3.0 for cervical
lymph node staging.8,34–37 In our study, we found an
SUV max of 3.7 or higher on the ipsilateral side, trans-
lating to a sensitivity of 87% and a specificity of 64%
with regard to malignancy. For the contralateral side, an
SUV max of 3.5 or higher translates to a sensitivity of
74% and a specificity of 76% with regard to malignancy.
After all, the published values are over a wide range
and also differ from what we have found in this study.
Therefore, we do not believe that one single SUV value
will emerge that can differentiate tumor from inflamed
nodes. Further, there is a difference to be found between
the ipsi- and the contralateral side, showing a potential
danger for misinterpreting 18F-FDG-PET/ CT findings,
especially on the contralateral side. In a previous study,
we have looked at different histopathological parameters
and correlated them with SUV max and its predictive
value. We found a correlation with advanced T-classifica-
tion only.38 The controversy in using SUV max to
diagnose malignancy is ongoing. In our opinion, the
interpretation of 18F-FDG-PET/ CT findings regarding
regional disease should be based primarily on visual
findings looking at the morphology and shape of the
lymph nodes and not essentially on SUV measurements.
Furthermore, a contrast-enhanced (ce) CT instead of a
native CT fused with an 18F-FDG-PET might be of more
importance to help with the problem of regional disease,
as shown in an earlier publication.39
Finally, we have looked at a potential correlation of
midline invasion of the primary in 18F-FDG-PET/ CT,
with true positive findings in the contralateral neck.
From a clinical aspect, the higher false positive 18F-
FDG-PET/ CT findings in the contralateral neck (65%
vs. 80%; P 5 0.067) in patients with lateralized tumors
is expected, given the spread pattern of HNSCC with a
lower pretest probability of metastasis in the contralat-
eral neck. However, and interestingly, midline invasion
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of the primary tumor was not found to be associated
with a higher true positive rate for the contralateral
neck (P 5 0.82). This may be due to peritumoral inflam-
mation overstaging the primary tumor with increased
18F-FDG-uptake. In summary, the complex anatomical
structures and the presence of benign tissue showing
physiological 18F-FDG-uptake make the head and neck
region a complex part of the body for interpreting meta-
bolic imaging.40
The authors acknowledge the potential limitation
on the reported findings as a consequence of having had
to eliminate one-third of the selected patient cohort due
to missing data.
CONCLUSION
18F-FDG uptake differs between the ipsi- and con-
tralateral side of the neck in patients suffering from
HNSCC. A high SUV max in the contralateral neck
suggests metastatic disease regardless of nodal size. The
implications of the study are to prevent unnecessary neck
dissections and radiation to uninvolved necks. Due to our
results we recommend proper analyses of each suspicious
FDG accumulation. This work might be a small step
towards a more patient-centered medicine with more
individualized therapy. Midline invasion detected by 18F-
FDG-PET/ CT needs to be addressed carefully as it was
not predictive for bilateral lymph node involvement.
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